Insider Selling: Disc Medicine (NASDAQ:IRON) CEO Sells 33,000 Shares

Disc Medicine, Inc. (NASDAQ:IRON) CEO John Quisel sold 33,000 shares of the firm’s stock in a transaction that occurred on Monday, July 13th. The shares were sold at an average price of $74.96, for a total value of $2,473,680.00. Following the completion of the sale, the chief executive officer directly owned 226,064 shares in the company, valued at approximately $16,945,757.44. The trade was a 12.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Disc Medicine Price Performance

Shares of IRON stock traded down $0.97 during trading hours on Tuesday, hitting $75.01. 362,830 shares of the company’s stock were exchanged, compared to its average volume of 620,606. Disc Medicine, Inc. has a fifty-two week low of $40.00 and a fifty-two week high of $99.50. The firm has a market cap of $2.86 billion, a P/E ratio of -11.33 and a beta of 0.97. The company has a quick ratio of 24.00, a current ratio of 24.00 and a debt-to-equity ratio of 0.04. The firm has a 50 day moving average of $70.62 and a two-hundred day moving average of $70.00.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($1.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.62) by ($0.03). Sell-side analysts forecast that Disc Medicine, Inc. will post -6.74 EPS for the current year.

Hedge Funds Weigh In On Disc Medicine

A number of institutional investors and hedge funds have recently bought and sold shares of IRON. RA Capital Management L.P. grew its stake in Disc Medicine by 25.3% during the 4th quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company’s stock valued at $156,925,000 after acquiring an additional 399,026 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Disc Medicine by 22.1% during the 4th quarter. Vanguard Group Inc. now owns 1,767,680 shares of the company’s stock worth $140,371,000 after purchasing an additional 319,621 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Disc Medicine by 28.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,698,005 shares of the company’s stock valued at $134,839,000 after purchasing an additional 371,576 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Disc Medicine by 110.0% in the fourth quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company’s stock valued at $125,557,000 after purchasing an additional 828,248 shares in the last quarter. Finally, Wellington Management Group LLP increased its holdings in shares of Disc Medicine by 7.7% in the fourth quarter. Wellington Management Group LLP now owns 1,518,274 shares of the company’s stock valued at $120,566,000 after purchasing an additional 108,197 shares during the last quarter. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on IRON. Wall Street Zen raised shares of Disc Medicine from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research note on Monday, April 20th. Wedbush reiterated an “outperform” rating and issued a $88.00 price objective on shares of Disc Medicine in a report on Wednesday, June 10th. Finally, Morgan Stanley boosted their price objective on Disc Medicine from $80.00 to $85.00 and gave the stock an “overweight” rating in a research note on Monday, June 15th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $104.44.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.